bluuebunny/crossref_metadata_2025 huggingface dataset:
Supp Figure 2 from HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1
Authors: Vandyke Kate , Zeissig Mara N. , Hewett Duncan R. , Martin Sally K. , Mrozik Krzysztof M. , Cheong Chee Man , Diamond Peter , To L. Bik , Gronthos Stan , Peet Daniel J. , Croucher Peter I. , Zannettino Andrew C.W.
Published: April 2023

Supp. Figure 2. Migration towards CXCL12 and cell surface CXCR4 expression is downregulated by CXCL12 treatment
Supplementary Materials and MEthods, Supplementary Tables 1 through 3, and Supplementary Figures 1 through 6 from Androgen-Dependent Repression of ERRγ Reprograms Metabolism in Prostate Cancer
Authors: Audet-Walsh Étienne , Yee Tracey , McGuirk Shawn , Vernier Mathieu , Ouellet Carlo , St-Pierre Julie , Giguère Vincent
Published: April 2023

The files contains extended Materials and Methods, Supplementary Table 1 and 2 contains primer sequences, Supplementary Table 3 contains Cox Regression Analysis, Figure S1 presents ChIP-sequencing data, Figure S2 show regulation of expression of ERRg by the androgen receptor, Figure S3 shows ERRg control of metabolic gene expression, Figure S4 and S5 ERRg control of prostate cancer cell metabolism, Figure S6 shows ERRa expression in relation to prostate cancer recurrence.
Figure S8 from β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Authors: Bucsek Mark J. , Qiao Guanxi , MacDonald Cameron R. , Giridharan Thejaswini , Evans Lauren , Niedzwecki Brian , Liu Haichao , Kokolus Kathleen M. , Eng Jason W.-L. , Messmer Michelle N. , Attwood Kristopher , Abrams Scott I. , Hylander Bonnie L. , Repasky Elizabeth A.
Published: April 2023

This figure shows that similar to our observations in mice treated with only propranolol, treating 4T1 tumor-bearing mice with anti-PD-1 and propranolol does not increase the frequency or relative number of CD8+ T cells in tumors.
Figure S7 from β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Authors: Bucsek Mark J. , Qiao Guanxi , MacDonald Cameron R. , Giridharan Thejaswini , Evans Lauren , Niedzwecki Brian , Liu Haichao , Kokolus Kathleen M. , Eng Jason W.-L. , Messmer Michelle N. , Attwood Kristopher , Abrams Scott I. , Hylander Bonnie L. , Repasky Elizabeth A.
Published: April 2023

This figure shows that treating B16-OVA tumor-bearing mice that are cold stressed due to mandated housing at 22 degrees C with propranolol improves the efficacy of anti-PD-1 in the B16-OVA tumor model.
Supplemental figure legends from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

supplemental figure legends
Figure S5 from β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Authors: Bucsek Mark J. , Qiao Guanxi , MacDonald Cameron R. , Giridharan Thejaswini , Evans Lauren , Niedzwecki Brian , Liu Haichao , Kokolus Kathleen M. , Eng Jason W.-L. , Messmer Michelle N. , Attwood Kristopher , Abrams Scott I. , Hylander Bonnie L. , Repasky Elizabeth A.
Published: April 2023

This figures shows data from a kinetic study in which we assessed MDSC burden at various early time-points as opposed to endpoint in Figure 4. This data shows that propranolol treatment reduces MDSC accumulation in spleens even when tumors are the same size as controls.
Supplemental figure 6 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Expression of exogenous Bcl-XL rescues ABBV-075 induced apoptosis but not cell cycle arrest
Supplemental figure 4 & 5 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Down regulation of Bcl-XL by MS417 and ABBV-075
Supplemental figure 21 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

ABBV-075 induces differentiation markers in HL-60 cells
Supplementary Figure Legends from Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression
Authors: Wang Li-Ting , Chiou Shyh-Shin , Chai Chee-Yin , Hsi Edward , Yokoyama Kazunari K. , Wang Shen-Nien , Huang Shau-Ku , Hsu Shih-Hsien
Published: April 2023

Supplementary Information
Supplemental figure 19 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Tumor environmental factors such as hypoxia or the presence of prosurvival cytokine such as IL-6 does not significantly change cellular sensitivity to ABBV-075
Supplemental figure 18 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Azacitidine enhance the degree of transcription regulation of a subset of ABBV-075-responsive genes
Supplemental figure 14 to 17 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

High level of concomitant Bim and Bcl-2 expression correlates with sensitivity to ABBV-075-induced apoptosis
Supplementary Fig. 5 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Sun Mianen , Tong Pan , Kong Wen , Dong Baijun , Huang Yiran , Park In Young , Zhou Lijun , Liu Xian-De , Ding Zhiyong , Zhang Xuesong , Bai Shanshan , German Peter , Powell Reid , Wang Quan , Tong Xuefei , Tannir Nizar M. , Matin Surena F. , Rathmell W. Kimryn , Fuller Gregory N. , McCutcheon Ian E. , Walker Cheryl L. , Wang Jing , Jonasch Eric
Published: April 2023

Loss of both Bub1b and Rb1 produced a polynuclear phenotype and larger cell size.
Supplementary Fig. 3 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Sun Mianen , Tong Pan , Kong Wen , Dong Baijun , Huang Yiran , Park In Young , Zhou Lijun , Liu Xian-De , Ding Zhiyong , Zhang Xuesong , Bai Shanshan , German Peter , Powell Reid , Wang Quan , Tong Xuefei , Tannir Nizar M. , Matin Surena F. , Rathmell W. Kimryn , Fuller Gregory N. , McCutcheon Ian E. , Walker Cheryl L. , Wang Jing , Jonasch Eric
Published: April 2023

Depletion of Hnf1b did not affect time from NEB to anaphase.
Supplementary Fig. 2 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Sun Mianen , Tong Pan , Kong Wen , Dong Baijun , Huang Yiran , Park In Young , Zhou Lijun , Liu Xian-De , Ding Zhiyong , Zhang Xuesong , Bai Shanshan , German Peter , Powell Reid , Wang Quan , Tong Xuefei , Tannir Nizar M. , Matin Surena F. , Rathmell W. Kimryn , Fuller Gregory N. , McCutcheon Ian E. , Walker Cheryl L. , Wang Jing , Jonasch Eric
Published: April 2023

Knockdown of Hnf1b led to polyploidy, CIN and checkpoint protein expression reduction in immortalized MEFs.
Supplementary Fig. 1 from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Sun Mianen , Tong Pan , Kong Wen , Dong Baijun , Huang Yiran , Park In Young , Zhou Lijun , Liu Xian-De , Ding Zhiyong , Zhang Xuesong , Bai Shanshan , German Peter , Powell Reid , Wang Quan , Tong Xuefei , Tannir Nizar M. , Matin Surena F. , Rathmell W. Kimryn , Fuller Gregory N. , McCutcheon Ian E. , Walker Cheryl L. , Wang Jing , Jonasch Eric
Published: April 2023

FLCN mRNA level was not decreased in sporadic ChRCC.
Figure S1 from Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells
Authors: Rohira Aarti D. , Yan Fei , Wang Lei , Wang Jin , Zhou Suoling , Lu Andrew , Yu Yang , Xu Jianming , Lonard David M. , O'Malley Bert W.
Published: April 2023

Figure S1 shows that SRC-3 coactivates TGFβ signaling through interaction with SMAD3
Supplementary Materials and Methods from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance
Authors: Zheng Xiaohu , Fan Xiaolei , Fu Binqing , Zheng Meijuan , Zhang Aimei , Zhong Kai , Yan Jialai , Sun Rui , Tian Zhigang , Wei Haiming
Published: April 2023

Supplementary Materials and Methods including Antibody staining, clinical samples information, ADCC/ADCP, chemotherapeutic drug treatment, xenograft model establishing, cell sorting, colony formation and tumorigenicity, magnetic resonance imaging and bone immunofluorescence.
Supplemental Figure Legends from Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity
Authors: Zheng Shunsheng , Koh Xin Yu , Goh Hui Chin , Rahmat Siti Aishah B. , Hwang Le-Ann , Lane David P.
Published: April 2023

Contain Legends for Supplementary Figures
Supplementary Figures from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance
Authors: Zheng Xiaohu , Fan Xiaolei , Fu Binqing , Zheng Meijuan , Zhang Aimei , Zhong Kai , Yan Jialai , Sun Rui , Tian Zhigang , Wei Haiming
Published: April 2023

Supplementary Figure 1. Immunofluorescence and flow cytometry staining for EpCAM in leukemia and normal samples and leukemia cell lines. Supplementary Figure 2. Microarray analysis of markedly up-regulated genes in EpCAM-high cells relative to EpCAM-low cells. Supplementary Figure 3. EpCAM-high K562 cells are similar to tumor stem cells. Supplementary Figure 4. Analysis of AE7 specificity by flow cytometry and IHC/IF staining. Supplementary Figure 5. Analysis of the anti-tumor effect of EpCAM antibody in vivo (lung cancer, positive control) and in vitro. Supplementary Figure 6. Analysis of macrophage clearance after clodronate liposome injection by IF staining.
Figure S5 from Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity
Authors: Zheng Shunsheng , Koh Xin Yu , Goh Hui Chin , Rahmat Siti Aishah B. , Hwang Le-Ann , Lane David P.
Published: April 2023

Supplementary Figure S5. Related to Figure 6 and 7. C646 protects bone marrow function while preserving doxorubicin efficacy.
Supplementary Figure legends from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance
Authors: Zheng Xiaohu , Fan Xiaolei , Fu Binqing , Zheng Meijuan , Zhang Aimei , Zhong Kai , Yan Jialai , Sun Rui , Tian Zhigang , Wei Haiming
Published: April 2023

Supplementary Figure 1-6 legends
Figure S4 from Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity
Authors: Zheng Shunsheng , Koh Xin Yu , Goh Hui Chin , Rahmat Siti Aishah B. , Hwang Le-Ann , Lane David P.
Published: April 2023

Supplementary Figure S4. Related to Figure 5. C646 selectively protects human bone marrow over colorectal cancer cells.
Figure S2 from Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity
Authors: Zheng Shunsheng , Koh Xin Yu , Goh Hui Chin , Rahmat Siti Aishah B. , Hwang Le-Ann , Lane David P.
Published: April 2023

Supplementary Figure S2. Related to Figure 2. C646 prevents specific p53 lysines from acetylation.
Figure S1 from Inhibiting p53 Acetylation Reduces Cancer Chemotoxicity
Authors: Zheng Shunsheng , Koh Xin Yu , Goh Hui Chin , Rahmat Siti Aishah B. , Hwang Le-Ann , Lane David P.
Published: April 2023

Supplementary Figure S1. Related to Figure 1. Unravelling the mechanism of C646 action.
Supplementary Figure Legends from STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway
Authors: Jin Lin , Vu Trung , Yuan Guandou , Datta Pran K.
Published: April 2023

These figure legends describe the presentation for supplementary figures (1-6).
Supplementary Figures_S1-S6 from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
Authors: Zhao Yuechao , Laws Mary J. , Guillen Valeria Sanabria , Ziegler Yvonne , Min Jian , Sharma Abhishek , Kim Sung Hoon , Chu David , Park Ben Ho , Oesterreich Steffi , Mao Chengjian , Shapiro David J. , Nettles Kendall W. , Katzenellenbogen John A. , Katzenellenbogen Benita S.
Published: April 2023

Figure S1 shows the dose-dependent inhibition of proliferation of T47D cells with wild type or mutant ERα by antiestrogen compounds. Figure S2 shows that the three antiestrogen compounds (K-07, K-09, K-62) and trans-hydroxytamoxifen suppress binding of the coregulator SRC3 to wild type ER and mutant ERs (Y537S, D538G). Figure S3 shows that antiestrogen compounds suppress the proliferation of MCF7 cells or T47D cells containing half mutant and half wild type ERα. Figure S4 shows that antiestrogen compounds induce ERα down-regulation in MCF7 and T47D cells containing half mutant and half wild type ERα. Figure S5 shows that antiestrogen compounds suppress ERα-regulated gene expressions in MCF7 and T47D cells containing half mutant and half wild type ERα. Figure S6 shows that treatment with antiestrogen compounds does not affect the body weights of mice bearing MCF7 xenograft tumors.
Supplementary Figures from VHL Inactivation in Precancerous Kidney Cells Induces an Inflammatory Response via ER Stress–Activated IRE1α Signaling
Authors: Kuo Chan-Yen , Lin Chih-Hung , Hsu Tien
Published: April 2023

Supplementary Figures provide: â€¢ Background information (Fig. S1) â€¢ Repeat/duplicate experiments (Figs. S2-S6 and S8). â€¢ Quantification of Western blot analyses (Fig. S3-S6) â€¢ Control experiments (Fig. S7)
Supplementary Tables 1-2 from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Authors: Vaishnavi Aria , Schubert Laura , Rix Uwe , Marek Lindsay A. , Le Anh T. , Keysar Stephen B. , Glogowska Magdalena J. , Smith Matthew A. , Kako Severine , Sumi Natalia J. , Davies Kurtis D. , Ware Kathryn E. , Varella-Garcia Marileila , Haura Eric B. , Jimeno Antonio , Heasley Lynn E. , Aisner Dara L. , Doebele Robert C.
Published: April 2023

Table 1: Cell lines, fusions, tyrosine kinase inhibitors and targets. Table 2: IC50 values for Figure 1C and relative fold change.
Figures S1-9 and Legends from EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Authors: Vaishnavi Aria , Schubert Laura , Rix Uwe , Marek Lindsay A. , Le Anh T. , Keysar Stephen B. , Glogowska Magdalena J. , Smith Matthew A. , Kako Severine , Sumi Natalia J. , Davies Kurtis D. , Ware Kathryn E. , Varella-Garcia Marileila , Haura Eric B. , Jimeno Antonio , Heasley Lynn E. , Aisner Dara L. , Doebele Robert C.
Published: April 2023

Fig. S1: EGFR inhibition or stimulation affects normal and catalytically inactive fusion oncogene signaling. Fig. S2: EGFR knockdown reduces fusion kinase cancer cell proliferation. Fig. S3: Conserved re-phosphorylated activation loop tyrosines enabled signaling PLA design and representative image analyses of fusion kinase and EGFR signaling PLAs. Fig. S4: Optimization of the EGFR-GRB2 PLA and fusion kinase PLA antibody controls. Fig. S5: The GRB2 adaptor does not switch from ROS1 to MET with FKI treatment, but MET can signal through GRB2. FIg. S6: GRB2 and SHC1 signaling rewire in a RET+ cell line treated with a fusion kinase inhibitor (FKI). Fig. S7: TRK, RET, ROS1 and ALK fusion kinases interact specifically with EGFR. Fig. S8: EGFR is highly expressed, phosphorylated, and signaling in vivo in an NTRK1+ patient-derived xenograft (PDX) model. Fig. S9: Fusion kinase, and EGFR signaling complexes are present in RET, and ALK, fusion resistant patient samples.
Supplementary Tables and Figures from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
Authors: Rivera Barbara , Di Iorio Massimo , Frankum Jessica , Nadaf Javad , Fahiminiya Somayyeh , Arcand Suzanna L. , Burk David L. , Grapton Damien , Tomiak Eva , Hastings Valerie , Hamel Nancy , Wagener Rabea , Aleynikova Olga , Giroux Sylvie , Hamdan Fadi F. , Dionne-Laporte Alexandre , Zogopoulos George , Rousseau Francois , Berghuis Albert M. , Provencher Diane , Rouleau Guy A. , Michaud Jacques L. , Mes-Masson Anne-Marie , Majewski Jacek , Bens Susanne , Siebert Reiner , Narod Steven A. , Akbari Mohammad R. , Lord Christopher J. , Tonin Patricia N. , Orthwein Alexandre , Foulkes William D.
Published: April 2023

This file includes supplementary Figure S1, Supplementary Figure S2 and Supplementary Figure S3. It also includes Supplementary Table S1 - RAD51D c.620C
Supplementary Table 3 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
Authors: Rivera Barbara , Di Iorio Massimo , Frankum Jessica , Nadaf Javad , Fahiminiya Somayyeh , Arcand Suzanna L. , Burk David L. , Grapton Damien , Tomiak Eva , Hastings Valerie , Hamel Nancy , Wagener Rabea , Aleynikova Olga , Giroux Sylvie , Hamdan Fadi F. , Dionne-Laporte Alexandre , Zogopoulos George , Rousseau Francois , Berghuis Albert M. , Provencher Diane , Rouleau Guy A. , Michaud Jacques L. , Mes-Masson Anne-Marie , Majewski Jacek , Bens Susanne , Siebert Reiner , Narod Steven A. , Akbari Mohammad R. , Lord Christopher J. , Tonin Patricia N. , Orthwein Alexandre , Foulkes William D.
Published: April 2023

'Supplementary Table3 -Presence of allelic imbalanced alleles in RAD51D and TP53 somatic mutations in RAD51D c.620C>T;p.S207L HGSC carriers.'
Supplementary Table 2 from Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma
Authors: Rivera Barbara , Di Iorio Massimo , Frankum Jessica , Nadaf Javad , Fahiminiya Somayyeh , Arcand Suzanna L. , Burk David L. , Grapton Damien , Tomiak Eva , Hastings Valerie , Hamel Nancy , Wagener Rabea , Aleynikova Olga , Giroux Sylvie , Hamdan Fadi F. , Dionne-Laporte Alexandre , Zogopoulos George , Rousseau Francois , Berghuis Albert M. , Provencher Diane , Rouleau Guy A. , Michaud Jacques L. , Mes-Masson Anne-Marie , Majewski Jacek , Bens Susanne , Siebert Reiner , Narod Steven A. , Akbari Mohammad R. , Lord Christopher J. , Tonin Patricia N. , Orthwein Alexandre , Foulkes William D.
Published: April 2023

'Supplementary Table S2- Somatic mutations identified in the tumors from individuals III.6; III.7 and III.8 in family 1 and individual III.1 in family 2 among 193 DNA repair genes.'
Supplemental legends from SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth
Authors: Zou Xianghui , Zhu Yueming , Park Seong-Hoon , Liu Guoxiang , O'Brien Joseph , Jiang Haiyan , Gius David
Published: April 2023

Supplemental legends
supplemental figure legends from Acetylation of Mastermind-like 1 by p300 Drives the Recruitment of NACK to Initiate Notch-Dependent Transcription
Authors: Jin Ke , Zhou Wen , Han Xiaoqing , Wang Zhiqiang , Li Bin , Jeffries Shawn , Tao Wensi , Robbins David J. , Capobianco Anthony J.
Published: April 2023

supplemental figure legends
Supplementary Figures from Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint
Authors: Green Abby M. , Budagyan Konstantin , Hayer Katharina E. , Reed Morgann A. , Savani Milan R. , Wertheim Gerald B. , Weitzman Matthew D.
Published: April 2023

Supplementary Figure S1 APOBEC3B outlier expression is rare in AML. Supplementary FIgure S2. Checkpoint activation depends on the deaminase activity of A3A. Supplementary Figure S3. RPA foci accumulate upon A3A expression. Supplementary Figure S4. ATR is activated by A3A expression in different leukemia phenotypes. Supplementary Figure S5. Genetic abrogation of ATM does not impact survival of cells with high A3A expression. Supplementary Figure S6. Cell cycle arrest caused by A3A is abrogated by replication checkpoint inhibitors.
Supplementary table 2_ CSF3R targeted deep sequencing result from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function
Authors: Zhang Haijiao , Means Sophie , Schultz Anna Reister , Watanabe-Smith Kevin , Medeiros Bruno C. , Bottomly Daniel , Wilmot Beth , McWeeney Shannon K. , Kükenshöner Tim , Hantschel Oliver , Tyner Jeffrey W.
Published: April 2023

The file contains a table demonstrating CSF3R targeted deep sequencing result
Supplementary table 1_Somatic mutations identified by exome sequencing from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function
Authors: Zhang Haijiao , Means Sophie , Schultz Anna Reister , Watanabe-Smith Kevin , Medeiros Bruno C. , Bottomly Daniel , Wilmot Beth , McWeeney Shannon K. , Kükenshöner Tim , Hantschel Oliver , Tyner Jeffrey W.
Published: April 2023

This file contains a table listing somatic mutations identified by Exome sequencing in the index patient
Supplementary Tables from JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity
Authors: Ye Juan , Li Tian-Sheng , Xu Gang , Zhao Yi-Ming , Zhang Ning-Ping , Fan Jia , Wu Jian
Published: April 2023

table S1 showed all shRNA sequences used for lentiviral generation table S2 showed primer sequences for quantitative PCR assays table S3 showed all antibodies used for Western blot analysis and immunohistochemical staining
supplementary figures from Loss of FAM46C Promotes Cell Survival in Myeloma
Authors: Zhu Yuan Xiao , Shi Chang-Xin , Bruins Laura A. , Jedlowski Patrick , Wang Xuewei , Kortüm K. Martin , Luo Moulun , Ahmann Jonathan M. , Braggio Esteban , Stewart A. Keith
Published: April 2023

supplementary figure 1-10
methods from Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
Authors: Schlenker Ramona , Olguín-Contreras Luis Felipe , Leisegang Matthias , Schnappinger Julia , Disovic Anja , Rühland Svenja , Nelson Peter J. , Leonhardt Heinrich , Harz Hartmann , Wilde Susanne , Schendel Dolores J. , Uckert Wolfgang , Willimsky Gerald , Noessner Elfriede
Published: April 2023

constructs, murine HCC model, spheroid and imaging, RCC tissue pathology
Supplementary table 5 from Loss of FAM46C Promotes Cell Survival in Myeloma
Authors: Zhu Yuan Xiao , Shi Chang-Xin , Bruins Laura A. , Jedlowski Patrick , Wang Xuewei , Kortüm K. Martin , Luo Moulun , Ahmann Jonathan M. , Braggio Esteban , Stewart A. Keith
Published: April 2023

Pathway analysis of the genes differeentially expressed in OCIMY5 cell after depletion of FAM46C. The genes were determined as differentially expressed were submitted to Ingenuity Pathway Analysis (IPA,http://www.ingenuity.com/) for pathway enrichment analysis. The results of top twenty four pathways affected were shown.
Supplementary table 4 from Loss of FAM46C Promotes Cell Survival in Myeloma
Authors: Zhu Yuan Xiao , Shi Chang-Xin , Bruins Laura A. , Jedlowski Patrick , Wang Xuewei , Kortüm K. Martin , Luo Moulun , Ahmann Jonathan M. , Braggio Esteban , Stewart A. Keith
Published: April 2023

The genes differeentially expressed in OCIMY5 cell after depletion of FAM46C. Gene expression analysis was performed to detect differentially expressed genes after depletion of FAM46C in OCIMY5 cells with two CRSPRs. Differentially expressed genes between FAM46C knockout and NS were identified using Affymetrix Transcriptome Analysis Console (with one-way ANNOVA approach), with p-value cutoff at 0.05 and fold change cutoff at 1.5.
Supplementary Figures 1 through 11 from Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment
Authors: Liu Yang , Pandeswara Srilakshmi , Dao Vinh , Padrón Álvaro , Drerup Justin M. , Lao Shunhua , Liu Aijie , Hurez Vincent , Curiel Tyler J.
Published: April 2023

Supplementary figure 1. Rapamycin reduces EL4 bone marrow infiltration. Supplementary figure 2. HD rapamycin impairs T cell activation and infiltration. Supplementary figure 3. Effects of rapamycin on mTOR signals and Ki67 (proliferation) in EL4 cells studied ex vivo. Supplementary figure 4. Dose response effects of rapamycin on EL4 in vivo. Supplementary figure 5. EL4 is refractory to many standard immunotherapies. Supplementary figure 6. LD rapamycin plus DD-mediated EL4 cell death is not blocked by anti-CD25 in vivo. Supplementary figure 7. LD rapamycin improves DD treatment efficacy of B16F10. Supplementary figure 8. Rapamycin + DD killing of EL4 and B16 cells is blocked with anti-CD25 + anti-CD22 in vitro. Supplementary figure 9. CD25 and CD122 expression are not upregulated by rapamycin treatment in vitro in mouse tumor lines B16F10 or ID8agg. Supplementary figure 10. CD25 and CD122 expression are not upregulated by rapamycin treatment in vivo in mouse challenged with B16F10. Supplementary figure 11. CD25 and CD122 expression on human NM001 and Jurkat cell lines is unchanged with temsirolimus in vitro.
Supplementary table 2 from Loss of FAM46C Promotes Cell Survival in Myeloma
Authors: Zhu Yuan Xiao , Shi Chang-Xin , Bruins Laura A. , Jedlowski Patrick , Wang Xuewei , Kortüm K. Martin , Luo Moulun , Ahmann Jonathan M. , Braggio Esteban , Stewart A. Keith
Published: April 2023

The differentially expressed genes after introduction exogenous FAM46C. RNAseq was performed on two cell lines (MM1.S and KMS11) after introduction of wild type FAM46C. Genes were determined as differentially expressed based on the criteria (RPKM >=3 in at least two samples, p-value <=0.05 and fold change >= 1.5).
Supplementary Tables 1-3 from Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations
Authors: Lim Byungho , Mun Jihyeob , Kim Yong Sung , Kim Seon-Young
Published: April 2023

Supplementary Tables S1 and S2 describes the datasets used in this study. Supplementary Table 3 is a table of correlation between histone marks and NER activities
Supplementary data from Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation
Authors: Nie Yan , Chen Jianing , Huang Di , Yao Yandan , Chen Jiewen , Ding Lin , Zeng Jiayi , Su Shicheng , Chao Xue , Su Fengxi , Yao Herui , Hu Hai , Song Erwei
Published: April 2023

These supplementary data contain supplementary methods
Figure S1 from Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Authors: Prat Aleix , Navarro Alejandro , Paré Laia , Reguart Noemí , Galván Patricia , Pascual Tomás , Martínez Alex , Nuciforo Paolo , Comerma Laura , Alos Llucia , Pardo Nuria , Cedrés Susana , Fan Cheng , Parker Joel S. , Gaba Lydia , Victoria Iván , Viñolas Nuria , Vivancos Ana , Arance Ana , Felip Enriqueta
Published: April 2023

Expression of the 23 genes and signatures across the 3 cancer groups in the nCounter-based dataset
Figure S4 from Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation
Authors: Nie Yan , Chen Jianing , Huang Di , Yao Yandan , Chen Jiewen , Ding Lin , Zeng Jiayi , Su Shicheng , Chao Xue , Su Fengxi , Yao Herui , Hu Hai , Song Erwei
Published: April 2023

CCL18 upregulates miR-21 expression and thus induces myoï¬�broblast differentiation via activiting NF-ÎºB.
Table S1 from Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation
Authors: Frandsen Stine K. , Krüger Mie B. , Mangalanathan Uma M. , Tramm Trine , Mahmood Faisal , Novak Ivana , Gehl Julie
Published: April 2023

Supplementary Table 1. Overview of conductivities. An overview of the conductivity used in the simulation of the electric field distribution in tumor, skin above, and muscle below treated with calcium electroporation. The system was constructed using three tissue (skin, tumor, and muscle) conductivity domains and the overall geometry was constructed as an extruded 2D geometry (Figure 4). The references for each of the conductivity domains are also shown in the table.
Figure S7 from Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation
Authors: Frandsen Stine K. , Krüger Mie B. , Mangalanathan Uma M. , Tramm Trine , Mahmood Faisal , Novak Ivana , Gehl Julie
Published: April 2023

Figure S7. Plasma membrane calcium ATPase (PMCA) mRNA level in normal and cancer cell lines Total PMCA, isoform 1, and isoform4 mRNA level in primary normal fibroblasts (HDF-n) and four cancer cell lines (H69, small cell lung cancer
Figure S8 from Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities
Authors: Méndez-Lucas Andrés , Li Xiaolei , Hu Junjie , Che Li , Song Xinhua , Jia Jiaoyuan , Wang Jingxiao , Xie Chencheng , Driscoll Paul C. , Tschaharganeh Darjus F. , Calvisi Diego F. , Yuneva Mariia , Chen Xin
Published: April 2023

Overexpress of PKM1 while silencing PKM2 in c-Myc induced liver tumors
Figure S6 from Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities
Authors: Méndez-Lucas Andrés , Li Xiaolei , Hu Junjie , Che Li , Song Xinhua , Jia Jiaoyuan , Wang Jingxiao , Xie Chencheng , Driscoll Paul C. , Tschaharganeh Darjus F. , Calvisi Diego F. , Yuneva Mariia , Chen Xin
Published: April 2023

Expression of glucolysis pathways enzymes (HKs and PFKs)
Figure S1 from Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation
Authors: Frandsen Stine K. , Krüger Mie B. , Mangalanathan Uma M. , Tramm Trine , Mahmood Faisal , Novak Ivana , Gehl Julie
Published: April 2023

Figure S1. Image of PVDF membrane showing total protein content in normal and cancer cell lines Total protein content elicited by staining with SimplyBlue SafeStain (Invitrogen) performed after western blotting of plasma membrane calcium ATPase (PMCA) expression in primary normal fibroblasts (HDF-n) and four cancer cell lines (H69, small cell lung cancer
Supplementary Figure 1-3 from Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling
Authors: Yin Jinlong , Oh Young Taek , Kim Jeong-Yub , Kim Sung Soo , Choi Eunji , Kim Tae Hoon , Hong Jun Hee , Chang Nakho , Cho Hee Jin , Sa Jason K. , Kim Jeong Cheol , Kwon Hyung Joon , Park Saewhan , Lin Weiwei , Nakano Ichiro , Gwak Ho-Shin , Yoo Heon , Lee Seung-Hoon , Lee Jeongwu , Kim Jong Heon , Kim Soo-Youl , Nam Do-Hyun , Park Myung-Jin , Park Jong Bae
Published: April 2023

Supplementary Figure 1 related to Figure 1. TGM2 is highly expressed in the necrotic region of MES GBM. Supplementary Figure 2 related to Figure 2. TGM2 regulates stemness of MES, PN, and CL GSCs. Supplementary Figure 3 related to Figure 4. A negative correlation between C/EBPβ and GADD153.
Figure S2 from Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities
Authors: Méndez-Lucas Andrés , Li Xiaolei , Hu Junjie , Che Li , Song Xinhua , Jia Jiaoyuan , Wang Jingxiao , Xie Chencheng , Driscoll Paul C. , Tschaharganeh Darjus F. , Calvisi Diego F. , Yuneva Mariia , Chen Xin
Published: April 2023

c-MYC/MCL1 induces liver tumor formation in mice with different genetic background
Figure S1 from Glucose Catabolism in Liver Tumors Induced by c-MYC Can Be Sustained by Various PKM1/PKM2 Ratios and Pyruvate Kinase Activities
Authors: Méndez-Lucas Andrés , Li Xiaolei , Hu Junjie , Che Li , Song Xinhua , Jia Jiaoyuan , Wang Jingxiao , Xie Chencheng , Driscoll Paul C. , Tschaharganeh Darjus F. , Calvisi Diego F. , Yuneva Mariia , Chen Xin
Published: April 2023

Sequences of miR-30 based shLuc, shPKM.1 and shPKM.2
Supplementary Fig S1-S12 from MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor–Initiating Cells
Authors: Wang Xiuxing , Huang Zhi , Wu Qiulian , Prager Briana C. , Mack Stephen C. , Yang Kailin , Kim Leo J.Y. , Gimple Ryan C. , Shi Yu , Lai Sisi , Xie Qi , Miller Tyler E. , Hubert Christopher G. , Song Anne , Dong Zhen , Zhou Wenchao , Fang Xiaoguang , Zhu Zhe , Mahadev Vaidehi , Bao Shideng , Rich Jeremy N.
Published: April 2023

Supplementary Figure 1. Induction of differentiation by BMP4 decreased expression of mevalonate synthesis enzymes (HMGCR, PMVK, MVK, MVD, IDI1 and FDPS). Supplementary Figure 2. Gene expression data from TCGA GBM patients revealed a high degree of co-expression of HMGCR, PMVK, MVK, MVD, IDI1 and FDPS. Supplementary Figure 3. Ivy glioblastomama atlas project (Ivy GAP) database analysis showed mevalonate pathway genes are enriched in invasive gliomas Supplementary Figure 4. Simvastatin induces cell cycle arrest in BTICs. Supplementary Figure 5. Simvastatin does not affect DGC proliferation. Supplementary Figure 6. Autophagy analysis showed that Simvastatin does not induce autophagy in BTICs. Supplementary Figure 7. Senescence analysis showed that Simvastatin does not cause senescence. Supplementary Figure 8. Apoptosis/ Necrosis analysis showed Simvastatin induces apoptosis in BTICs. Supplementary Figure 9. Farnesyltransferase inhibitor (FTI-277, 20 μM) and Geranylgeranyltransferase I inhibitor (GGTI-298, 10 μM) treatment decreased BTIC growth and self-renewal. Supplementary Figure 10. Farnesyl pyrophosphate (FPP, 20 μm/ml) can partially rescue the growth defect of BTICs induced by targeting MYC expression. Supplementary Figure 11. MYC and miR-33b expression were decreased when xenografted T3691 BTICs were treated with simvastatin (50mg/kg). Supplementary Figure 12. MiR-33b inhibitor treatment partially rescues the MYC protein levels and cellular growth defect caused by simvastatin.
Supplemental Figure 7 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Authors: Bartee Mee Y. , Dunlap Katherine M. , Bartee Eric
Published: April 2023

Gross histological examination of B16/F10 tumors treated with MYXV
Supplemental Figure 4 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Authors: Bartee Mee Y. , Dunlap Katherine M. , Bartee Eric
Published: April 2023

Efficacy of vPD1 therapy in the Lewis Lung Carcinoma model
Supplementary Tables 1, 2, 4, and 5 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Authors: Wali Vikram B. , Langdon Casey G. , Held Matthew A. , Platt James T. , Patwardhan Gauri A. , Safonov Anton , Aktas Bilge , Pusztai Lajos , Stern David F. , Hatzis Christos
Published: April 2023

Supplementary Table 1. Single doses selected for each drug from panel A. Supplementary Table 2. Layout of the two 384-well masterplates containing Panel B drugs. Supplementary Table 4. List of Top Synergistic Drug Combinations. Supplementary Table 5. Combination Index (CI) and Dose Reduction Index (DRI) values for the top drug combinations.
Supplemental Figure 1 from Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
Authors: Bartee Mee Y. , Dunlap Katherine M. , Bartee Eric
Published: April 2023

Elimination of PDL1 expression from B16/F10 tumor cells.
Supplementary Table 6 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Authors: Wali Vikram B. , Langdon Casey G. , Held Matthew A. , Platt James T. , Patwardhan Gauri A. , Safonov Anton , Aktas Bilge , Pusztai Lajos , Stern David F. , Hatzis Christos
Published: April 2023

Final MTS dataset used for analysis.
Table S2 from Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Authors: Jin Lingyan , Garcia Jesse , Chan Emily , de la Cruz Cecile , Segal Ehud , Merchant Mark , Kharbanda Samir , Raisner Ryan , Haverty Peter M. , Modrusan Zora , Ly Justin , Choo Edna , Kaufman Susan , Beresini Maureen H. , Romero F. Anthony , Magnuson Steven , Gascoigne Karen E.
Published: April 2023

RNA seq analysis of androgen stimulated LNCaP cells treated with GNE-049.
Table S1 from Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Authors: Jin Lingyan , Garcia Jesse , Chan Emily , de la Cruz Cecile , Segal Ehud , Merchant Mark , Kharbanda Samir , Raisner Ryan , Haverty Peter M. , Modrusan Zora , Ly Justin , Choo Edna , Kaufman Susan , Beresini Maureen H. , Romero F. Anthony , Magnuson Steven , Gascoigne Karen E.
Published: April 2023

Bromodomain selectivity data for GNE-049 using BROMOscan® panel
Supplemental Table S4 from Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability
Authors: Bieg-Bourne Cheyennedra C. , Millis Sherri Z. , Piccioni David E. , Fanta Paul T. , Goldberg Michael E. , Chmielecki Juliann , Parker Barbara A. , Kurzrock Razelle
Published: April 2023

Supplemental Table S4 displays the Foundation Medicine 404 Gene Panel for hematologic malignancies.
Figure S3 from Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Authors: Jin Lingyan , Garcia Jesse , Chan Emily , de la Cruz Cecile , Segal Ehud , Merchant Mark , Kharbanda Samir , Raisner Ryan , Haverty Peter M. , Modrusan Zora , Ly Justin , Choo Edna , Kaufman Susan , Beresini Maureen H. , Romero F. Anthony , Magnuson Steven , Gascoigne Karen E.
Published: April 2023

Western blot and ChIP seq analysis of GNE-049 impact on histone acetylation
Supplemental Table S2 from Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability
Authors: Bieg-Bourne Cheyennedra C. , Millis Sherri Z. , Piccioni David E. , Fanta Paul T. , Goldberg Michael E. , Chmielecki Juliann , Parker Barbara A. , Kurzrock Razelle
Published: April 2023

Supplemental Table S2 displays the Foundation Medicine 315 gene panel for solid tumors.
Figure S2 from Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Authors: Jin Lingyan , Garcia Jesse , Chan Emily , de la Cruz Cecile , Segal Ehud , Merchant Mark , Kharbanda Samir , Raisner Ryan , Haverty Peter M. , Modrusan Zora , Ly Justin , Choo Edna , Kaufman Susan , Beresini Maureen H. , Romero F. Anthony , Magnuson Steven , Gascoigne Karen E.
Published: April 2023

qPCR analysis of Myc expression after GNE-049 treatment, effects of GNE-049 combination treatment.
Supplementary Methods & Figures S1-S5 from Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Authors: Scher Howard I. , Graf Ryon P. , Schreiber Nicole A. , McLaughlin Brigit , Jendrisak Adam , Wang Yipeng , Lee Jerry , Greene Stephanie , Krupa Rachel , Lu David , Bamford Pascal , Louw Jessica E. , Dugan Lyndsey , Vargas Hebert A. , Fleisher Martin , Landers Mark , Heller Glenn , Dittamore Ryan
Published: April 2023

Supplementary Methods describe an alternative pipeline for measuring CTC phenotypic heterogeneity: the Pleomorphism index, which is further supported and depicted in Figures S5-S6. Figure S1 further describes and depicts the central hypothesis of the manuscript. Figure S2 shows the principal component analysis and k-means clustering used for phenotypic subtype classification. Figure S3 shows the correlation between Shannon index and other pre-therapy features. Figure S4 shows a multivariate analyses that excludes samples with Shannon index of 0.
Supplementary Information from Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression
Authors: Casadei Lucia , Calore Federica , Creighton Chad J. , Guescini Michele , Batte Kara , Iwenofu O. Hans , Zewdu Abeba , Braggio Danielle A. , Bill Kate Lynn , Fadda Paolo , Lovat Francesca , Lopez Gonzalo , Gasparini Pierluigi , Chen James L. , Kladney Raleigh D. , Leone Gustavo , Lev Dina , Croce Carlo M. , Pollock Raphael E.
Published: April 2023

Supplementary Table S1. Detailed information about patients (A) and control group (B)used in the discovery set; Supplementary Table S2. Detailed information about patients (A) and control group (B) used in the validation set; Supplementary Table S3. Detailed information about cancer tissue (A) and normal adjacent tissue (B) analyzed; Supplementary Table S4. Detailed information about additional patients whose tissues have been analyzed by immunohistochemistry (not previously reported); Supplementary Figure S1. Peripheral blood-derived EVs characterization (Nanosight); Supplementary Figure S2. LPS- secreted EVs characterization (Nanosight); Supplementary Figure S3. Expression levels of miR-25-3p and miR-92a-3p in EVs and LPS tissues; Supplementary Figure S4. Western blot analysis for phospho-p65; Supplementary Figure S5. miR-25-3p and miR-92a-3p stimulate the secretion of TNFα from macrophages
supplementary figures 1-5 from MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Authors: Lu Xinyuan , Peled Nir , Greer John , Wu Wei , Choi Peter , Berger Alice H. , Wong Sergio , Jen Kuang-Yu , Seo Youngho , Hann Byron , Brooks Angela , Meyerson Matthew , Collisson Eric A.
Published: April 2023

Supplementary Figure 1: A survey of MET mutations and expression across TCGA datasets from diverse cancer types. Supplementary figure 2, MET exon 14 status and trypsin assay Supplementary Figure 3 MET half-life assay results Supplementary Figure 4 tumor grade and size changes Supplementary Figure 5: Acquired resistance alleles are in trans
Supplementary Methods from MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma
Authors: Lu Xinyuan , Peled Nir , Greer John , Wu Wei , Choi Peter , Berger Alice H. , Wong Sergio , Jen Kuang-Yu , Seo Youngho , Hann Byron , Brooks Angela , Meyerson Matthew , Collisson Eric A.
Published: April 2023

Supplementary Methods
Supplementary Information from Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers
Authors: Peters Brandilyn A. , Wu Jing , Pei Zhiheng , Yang Liying , Purdue Mark P. , Freedman Neal D. , Jacobs Eric J. , Gapstur Susan M. , Hayes Richard B. , Ahn Jiyoung
Published: April 2023

Supplementary Figure 1: PCoA for quality control samples; Supplementary Figure 2: Rarefaction curves of richness and the Shannon index; Supplementary Figure 3: Forest plot of odds ratios by cohort; Supplementary Table 1: Quality control sample CVs and ICCs; Supplementary Table 2: alpha- and beta-diversity and EAC/ESCC; Supplementary Table 3: Oral taxa and EAC by years to case diagnosis; Supplementary Table 4: Oral taxa and EAC by cohort; Supplementary Table 5: Oral taxa and EAC by smoking; Supplementary Table 6: Oral taxa and EAC by obesity; Supplementary Table 7: Oral taxa and EAC by fruit/vegetable intake.
Supplementary Table S1 from A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents
Authors: Azan Antoine , Caspers Peter J. , Bakker Schut Tom C. , Roy Séverine , Boutros Céline , Mateus Christine , Routier Emilie , Besse Benjamin , Planchard David , Seck Atmane , Kamsu Kom Nyam , Tomasic Gorana , Koljenović Senada , Noordhoek Hegt Vincent , Texier Matthieu , Lanoy Emilie , Eggermont Alexander M.M. , Paci Angelo , Robert Caroline , Puppels Gerwin J. , Mir Lluis M.
Published: April 2023

Summary of the measurements of the drug concentration into patients' blood.
Figure S5 from Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1–Mediated Macrophage Infiltration
Authors: Sossey-Alaoui Khalid , Pluskota Elzbieta , Bialkowska Katarzyna , Szpak Dorota , Parker Yvonne , Morrison Chevaun D. , Lindner Daniel J. , Schiemann William P. , Plow Edward F.
Published: April 2023

This Figure reports Kaplan-Meier plot correlating survival of 3951 breast cancer patients with CSF-1 expression levels
Supplementary materials and methods from Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Authors: Miao Lei , Liu Qi , Lin C. Michael , Luo Cong , Wang Yuhua , Liu Lina , Yin Weiyan , Hu Shihao , Kim William Y. , Huang Leaf
Published: April 2023

Supplementary material and methods
Figure S2 from Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1–Mediated Macrophage Infiltration
Authors: Sossey-Alaoui Khalid , Pluskota Elzbieta , Bialkowska Katarzyna , Szpak Dorota , Parker Yvonne , Morrison Chevaun D. , Lindner Daniel J. , Schiemann William P. , Plow Edward F.
Published: April 2023

This figure contains tumor staining additional markers to support Figure 3F and Figure 3I
Table S1 from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

Differential gene expression lung NK cells at early stages of tumor progression compared to advanced stages
Table S1-S2 from SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic Stem Cell Differentiation
Authors: Kidder Benjamin L. , He Runsheng , Wangsa Darawalee , Padilla-Nash Hesed M. , Bernardo M. Margarida , Sheng Shijie , Ried Thomas , Zhao Keji
Published: April 2023

Table S1. Primer sequences for Q-RT-PCR Table S2. SKY Analysis of shLuc ES cells, shSmyd5 ES cells, and shSmyd5 cancer cells.
Supplementary Information from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

Includes figure legends for all the supplementary figures
Figure S4 from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

Expression of Lag-3, TIGIT and PD-1 on lung NK cells from IL-12-treated mice with LLC experimental metastasis
Figure S3 from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

IL-12 activates and increases the cytotoxicity of NK cells